This study is testing a new medicine called orforglipron to see how well it helps people who are obese or overweight, with or without type 2 diabetes. Obesity means having too much body fat, and overweight means weighing more than is healthy. Type 2 diabetes is a condition where the body has trouble using sugar for energy, leading to high blood sugar levels. The study will compare orforglipron to a placebo, which is a "fake" treatment with no active medicine, to check if it works and is safe.
- Participants will be screened for about 4 weeks before they start the study.
- After screening, participants will join either Study GZP1 (without type 2 diabetes) or GZP2 (with type 2 diabetes).
- Specific eligibility criteria are listed under each study, GZP1 and GZP2.
How understandable was the trial content above?
Hard to understand
Easy to understand